News

In an interview with Targeted Oncology, Charles Geyer, MD, discussed the data from the OlympiA clinical trial and how adjuvant olaparib could impact the treatment of BRCA-positive, HER2-negative breast cancer and other BRCA-positive women’s cancers.

Pembrolizumab is now an FDA-approved treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Solange Peters, MD, PhD, discusses the ways in which oncologists can manage toxicities in patients with unresectable malignant pleural mesothelioma.

The FDA has granted approval to the fixed-dose combination of relatlimab plus nivolumab for the treatment of adult and pediatric patients with unresectable or metastatic melanoma.

The FDA has released a draft of new recommendations for the manufacture, development, and study design of chimeric antigen receptor T cells.

Two medical oncologists become the are the latest board-certified, fellowship-trained physicians who have chosen to practice medicine at Cancer Treatment Centers of America.

Following the important information provided by the phase 3 VESPER trial, Jean Hoffman-Censits, Md said there are several noteworthy ongoing phase 3 neoadjuvant immunotherapy studies in bladder cancer.

Tafasitamab-cxi plus lenalidomide has been added to the NCCN Guidelines as a preferred regimen for patients with diffuse large B-cell lymphoma.

Orphan drug designation has been granted to TCB-002 for use as a potential therapeutic option in patients with relapsed/refractory acute myeloid leukemia.

In an interview with Targeted Oncology, Ghaith Abu-Zeinah, discussed the factors contributing to overall survival in patients with polycythemia vera and what is expected of future research.

Ming Zhao, MD, explains the background of the FOHAIC-1 study.

The FDA has approved the FoundationOne CDx as a companion diagnostic to identify patients with non–small cell lung cancer with tumors that harbor EGFR exon 19 deletions or exon 21 substitutions.

The KEYLYNK-010 trial of pembrolizumab and olaparib was terminated following negative overall survival results in patients with metastatic castration-resistant prostate cancer.

Selinexor shows statistically significant improvement in progression-free survival in patients with endometrial cancer.

In an interview with Targeted Oncology, Steven M. Albelda, MD, discussed the introduction of chimeric antigen receptor T cells in solid tumor research and how it differs from what has been observed in hematologic malignancies.

Three and a half-year follow-up in the OlympiA trial showed continued survival improvement and underscores the vitality of germline BRCA testing.

AON practices are focused on providing the best oncology care while also responsibly controlling cancer costs for patients and associated insurance plans.

Type C meeting with the FDA requested by Allarity to discuss potential clinical paths to support approval of dovitinib as a potential option in the third-line treatment of patients with renal cell carcinoma

The combination of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone bests the CHOP regimen in the treatment of patients with peripheral T-cell lymphoma.

Adding toripalimab to chemotherapy as frontline treatment for advanced non–small cell lung cancer crossed the boundary for statistical significance in CHOICE-01, meeting 2 study end points.

Cabozantinib in combination with atezolizumab shows no effect on survival compared to sorafenib in patients with previously untreated advanced hepatocellular carcinoma based on results from the final analysis of the phase 3 COSMIC-312 trial.

All primary end points in the phase 3 study of bempegaldesleukin plus nivolumab for the treatment of metastatic melanoma were missed, but analyses are ongoing.

Tracy Rose, MD, discussed the future of adjuvant and neoadjuvant therapy in muscle-invasive bladder cancer specifically using cisplatin-based regimens.

The AALL1231 trial of bortezomib showed survival benefit for children with T-cell lymphoblastic lymphoma and significantly reduced need for cranial radiotherapy in patients with T-cell acute lymphoblastic leukemia.

Carole Miller, MD, discusses the REVEAL study which enrolled patients with polycythemia vera at both academic and community practices.

An update from the phase 2 AMEERA-3 clinical trial shows that amcenestrant does not improve progression-free survival in ER-positive, HER2-negative breast cancer.

The FDA approved the BRACAnalysis CDx test for use as a companion diagnostic with adjuvant olaparib to identify patients with germline BRCA-mutated for patients with HER2 negative, high-risk early-stage breast cancer.

Cathy Eng, MD, discusses what can be done in order to integrate biomarker testing for anal cancer into clinical practice.

Ribociclib plus letrozole demonstrated statistically significant improvement in overall survival with the combination in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.

FDA approval has been granted to adjuvant olaparib for the treatment of BRCA-mutated, HER2-negative breast cancer.